Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene

Leukemia. 2004 May;18(5):1020-1. doi: 10.1038/sj.leu.2403338.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Fusion Proteins, bcr-abl / chemistry
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Piperazines / therapeutic use*
  • Polymerase Chain Reaction
  • Pyrimidines / therapeutic use*
  • RNA, Messenger / analysis

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl